Skip to main content
Premium Trial:

Request an Annual Quote

Medicare Contractor Issues Draft Local Coverage Determination for Veracyte Lung Cancer Test

NEW YORK (GenomeWeb) – Veracyte announced today that Medicare contractor Palmetto GBA has issued a draft local coverage determination (LCD) for the company's Percepta Bronchial Genomic Classifier.

"As anticipated, we are moving quickly toward securing draft Percepta LCDs from all four [Molecular Diagnostic Services] program participants," Veracyte President and CEO Bonnie Anderson said in a statement.

Obtaining Medicare coverage for Percepta since its early 2015 launch has been a key goal for Veracyte as it follows the the same commercialization strategy for the test as it did for its first diagnostic, the Afirma gene expression classifier for thyroid cancer.

Last week, Noridian, the nation's largest Medicare Administrative Contractor, issued its own draft LCD on the test, which is designed to identify patients at low risk of lung cancer following inconclusive bronchoscopy.

Other participants in the MolDx program include CGS Administrators and Wisconsin Physicians Service Insurance, or WPS.